Drug metabolism in SB612111-pretreated monkey plasma assessed as radiometabolite formation at 4.9 to 6.6 mCi, iv administered as bolus dose 10 mins post SB612111-treatment up to 100 mins
Metabolic stability in SB612111-pretreated monkey plasma at 4.9 to 6.6 mCi, iv administered as bolus dose 10 mins post SB612111-treatment up to 100 mins
Drug uptake in monkey lateral temporal cortex at 6.2 mCi, iv administered as bolus dose followed by naloxone-treatment at 37 mins measured at 120 mins by PET imaging analysis
Drug uptake in monkey amygdala at 6.2 mCi, iv administered as bolus dose followed by naloxone-treatment at 37 mins measured at 120 mins by PET imaging analysis
Drug uptake in monkey caudate at 6.2 mCi, iv administered as bolus dose followed by naloxone-treatment at 37 mins measured at 120 mins by PET imaging analysis
Drug uptake in monkey cerebellum at 6.2 mCi, iv administered as bolus dose followed by naloxone-treatment at 37 mins measured at 120 mins by PET imaging analysis
Drug uptake in monkey hypothalamus at 6.2 mCi, iv administered as bolus dose followed by naloxone-treatment at 37 mins measured at 120 mins by PET imaging analysis
Drug uptake in monkey lateral temporal cortex at 6.2 mCi, iv administered as bolus dose followed by SB612111-treatment at 40 mins measured at 100 mins by PET imaging analysis
Drug uptake in monkey amygdala at 6.2 mCi, iv administered as bolus dose followed by SB612111-treatment at 40 mins measured at 100 mins by PET imaging analysis
Drug uptake in monkey caudate at 6.2 mCi, iv administered as bolus dose followed by SB612111-treatment at 40 mins measured at 100 mins by PET imaging analysis
Drug uptake in monkey cerebellum at 6.2 mCi, iv administered as bolus dose followed by SB612111-treatment at 40 mins measured at 100 mins by PET imaging analysis